Composition of ifn-λ1 and immune checkpoint inhibitor and use thereof for treating ovarian cancer

Abstract

This invention provides a pharmaceutical composition comprising: IFN-λ1, an immune checkpoint inhibitor, and a pharmaceutically acceptable carrier, wherein the immune checkpoint inhibitor includes: a PD-L1 inhibitor, a PD-1 inhibitor, or a CTLA-4 inhibitor. Furthermore, it provides a treatment for ovarian cancer using IFN-λ1 or IFN-λ1 combined with an immune checkpoint inhibitor, effectively inhibiting the growth, deterioration, and metastasis of cancer cells, reducing ascites production, and simultaneously enhancing the individual's immune response.

Claims

1. A pharmaceutical composition comprising: IFN-λ1, immune checkpoint inhibitors, and pharmaceutically acceptable carriers, wherein the immune checkpoint inhibitors include: PD-L1 inhibitors and / or PD-1 inhibitors selected from the group consisting of: nivolumab, pembrolizumab, pitilizumab, IBI-308, BGB-108, mDX-400, and MED. I-0680, SHR-1210, PF-06801591, PDR-001, GB-226, STI-1110, atezolizumab, durvalumab, avelumab, BMS-936559, ALN-PDL, TSR-042, KD-033, CA-170, CA-327, STI-1014, and KY-1003.

2. The pharmaceutical composition as described in claim 1, wherein, The effective dose (HED) of this IFN-λ1 is 0.055 mg / kg to 0.1099 mg / kg, and when the immune checkpoint inhibitor is atezolizumab, its effective dose is 1.0989 mg / kg.

3. The pharmaceutical composition as claimed in claim 1, wherein the PD-L1 inhibitor has immunosuppressive function by inhibiting regulatory T cells, or the PD-1 inhibitor has immunosuppressive function by inhibiting regulatory T cells.

4. The pharmaceutical composition as claimed in claim 1, wherein the IFN-λ1 has anti-ovarian cancer tumor activity in vivo, and / or the immune checkpoint inhibitor has antibody-dependent cytotoxic activity.

5. One use of IFN-λ1 is for the preparation of a medicament for the treatment or prevention of ovarian cancer or its metastatic forms.

6. The use of a combination of IFN-λ1 and an immune checkpoint inhibitor for the preparation of a drug for the treatment or prevention of ovarian cancer, wherein the immune checkpoint inhibitor comprises a PD-L1 inhibitor and / or a PD-1 inhibitor selected from the group consisting of: nivolumab, pelizumab, pilizumab, IBI-308, BGB-108, mDX-400, MEDI-0680, SHR-1210, PF-06801591, PDR-001, GB-226, STI-1110, atezolizumab, durvalumab, avirumab, BMS-936559, ALN-PDL, TSR-042, KD-033, CA-170, CA-327, STI-1014, and KY-1003.

7. The use of the combination of IFN-λ1 and immune checkpoint inhibitors as described in claim 6, wherein the ovarian cancer is selected from the group consisting of stage I, stage II, stage III and stage IV ovarian cancer; wherein the ovarian cancer is selected from the group consisting of mucinous ovarian cancer, endometrioid ovarian cancer, clear cell ovarian cancer and serous ovarian cancer, or selected from the group consisting of Klugember's tumor of the ovary, ovarian carcinosarcoma, immature teratoma of the ovary, and ovarian mucinous and granulosa tumor.

Images